Microbix Biosystems Inc.

301 articles about Microbix Biosystems Inc.

• Microbix Presenting at the 2024 Bloom Burton Conference

  4/11/2024

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024.

• Microbix Announces Annual and Special Meeting Voting Results - April 01, 2024

  4/1/2024

  Microbix Biosystems Inc., a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company which was held on March 27, 2024.

• Microbix’s Clot-Buster Drug Project Advances

  3/14/2024

  Microbix Biosystems Inc. announces that its funding and commercialization partner, Sequel Pharma, LLC, has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization for production of the active ingredient of Kinlytic® urokinase, a biologic drug for dissolving blood clots.

• Microbix Unveils Test Controls for Head and Neck Cancer HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses

  3/11/2024

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it is presenting results of Quality Assessment Products for supporting the quality control of histology and PCR-based tests driven by tissue-samples of Head and Neck cancer caused by human papilloma virus.

• Microbix Announces Issuance of Stock Options - February 26, 2024

  2/26/2024

  Microbix Biosystems Inc. announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Reports Record Results for Q1 Fiscal 2024Record Revenues of $8.4 million and Record Net Income of $2.5 million

  2/14/2024

  Microbix Biosystems Inc. reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“ Q1 ”).

• Microbix Schedules Release of Results for Q1 Fiscal 2024 Results Release and Webinar Discussion on Morning of February 14, 2024

  2/7/2024

  Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements and management disclosure and analysis for its first quarter of fiscal 2024 ended December 31, 2023 prior to the start of trading on February 14, 2024.

• Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen

  2/6/2024

  Microbix Biosystems Inc. announces that it is presenting results of a Quality Assessment Product for supporting the clinical use and accuracy of molecular tests for infection with Helicobacter pylori, the bacterial cause of stomach ulcers, at Labquality Days, a lab diagnostics conference taking place in Helsinki, Finland from February 8 to 10, 2024.

• Microbix Achieves Further QAPs Sales RecordOver C$ 1 Million in One Shipment to a Leading Lab Accreditation Agency

  1/3/2024

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it has sold and shipped over one million Canadian Dollars of its quality assessment products to a leading agency that provides clinical laboratory accreditation services.

• Microbix Reports Results for Q4 & Full-Year Fiscal 2023Full-Year Sales of $16.5 million and Net Loss of $0.04 million

  12/21/2023

  Microbix Biosystems Inc. reports results for its year and fourth quarter ended September 30, 2023, with solid sales and a resumption of profitability in Q4, ongoing progress to increase revenues from its diagnostic-test related ingredients and devices, and recognition of a fully-funded program to revalidate and relaunch its approved drug, Kinlytic® urokinase.

• Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy Expanded Collaboration to Improve Syndromic Infectious Disease Testing

  12/14/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with Seegene USA, Inc., a leading developer of multiplex molecular assays and automated solutions for U.S. labs.

• Microbix & BioGX Collaborate on real-time PCR Assays & Controls

  12/7/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc., a global provider of easy molecular diagnostic solutions.

• Microbix Announces Initiation of Normal Course Issuer Bid

  12/6/2023

  Microbix Biosystems Inc. announces the initiation of a Normal Course Issuer Bid program for the repurchase and cancellation of outstanding common shares.

• Microbix Presenting at Florida Capital Event ConferenceMeetings with Growth-Oriented Investors, November 17 to 19, 2023

  11/17/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces that it will be presenting to investors at the Florida Capital Event Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Turnberry, in Aventura, Florida, November 17 to 19, 2023.

• Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market

  11/16/2023

  Microbix Biosystems Inc. announces the reconfirmation of its agreement with Sequel Pharma, LLC to return Kinlytic® urokinase to market, initially for dissolving blood clots that block venous catheters in the United States, followed by other geographies and clinical indications.

• Microbix & Ulisse Biomed Collaborate on HPV Controls & AssaysOnboarding Tools and Quality Controls for Extended Genotype HPV Assays

  11/10/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with Ulisse Biomed S.p.A., a company developing innovative diagnostics, theranostics, and therapeutics.

• Microbix QAPs Supporting HPV Testing in Ireland

  10/27/2023

  Microbix Biosystems Inc. announces that its quality assessment products are supporting a testing program for Human Papilloma Virus using molecular diagnostic technology at Dublin’s The Coombe Hospital, in the Republic of Ireland, an EU member-state.

• Microbix Presenting at Muskoka Capital Conference - September 29, 2023

  9/29/2023

  Microbix Biosystems Inc. announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, Ontario, September 29 to October 1, 2023.

• Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023

  9/13/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, honours the passing of its founder, William J. Gastle, surrounded by family in Edmonton, Alberta on September 6, 2023.

• Microbix Reports Results for Q3 Fiscal 2023

  8/10/2023

  Microbix Biosystems Inc. reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“ Q3 ” and “ YTD ”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic ® urokinase (“ Kinlytic ”).